Magle Group announced the establishment of a collaboration and exclusive worldwide distribution agreement with the global medical device company Sirtex Medial pertaining to its chemoembolization product EmboCept®? S DSM 50 um. The main purpose is to accelerate internationalization, drive growth in new geographic areas, and support the expansion of Magle Group's product portfolio in this important medical field.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32 SEK | 0.00% | 0.00% | +26.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.98% | 31.89M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- MAGLE Stock
- News Magle Chemoswed Holding AB
- Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um